Interview with Nicolas Poirier, CEO at OSE Immunotherapeutics a biotech with a compound that is a therapeutic cancer vaccine, ...

Can you tell me about the company? Mr. Poirier: Sure. OSE Immunotherapeutics is a French biotech — the company is listed on Euronext Paris — and we are developing immunotherapies. Specifically, these ...

CEO Silviu Itescu explains how Mesoblast changes a disease that is fatal 70% or 90% to a disease that can be cured.

Please give me an overview of the company and its services. Mr. Gonen: MediWound is a global leader in next generation enzymatic therapeutics for tissue repair. Our core active pharmaceutical ...

It’s been a few years since you spoke with The Wall Street Transcript. So, let’s start with a brief overview and history of the company. Dr. Itescu: Sure. So, we’re a mature company. We’re listed on ...

We spoke about two years ago. How would you compare today’s market to back then? Mr. Vandermosten: Two years ago would have been fall 2022, and I think we had seen about a year of pullback in the life ...

First please introduce your firm and your coverage. You recently said that this is a very problematic market. Why so? What prompts the change in your outlook? Dr. Brozak: I am President of WBB ...

So let’s start with a brief history of the company and its mission. Mr. Pilcher: Sure. So Neuren is an interesting company, which has had a long history and a couple of incarnations. Twenty years ago ...

Please provide an overview of your coverage and the subsectors, cap sizes, and primary names that you follow. Mr. Beatty: I cover biotech. And within biotech, most of my coverage is within the ...

Could you tell me about Premier? Mr. Alkire: Sure. Premier is a health care improvement company. We have two different segments to our business. We have a supply chain segment and a performance ...

The Wall Street Transcript is a completely unique resource for investors and business researchers.

The Wall Street Transcript is a completely unique resource for investors and business researchers.